New COVID-19 Test Uses Nanotube-Based Electrochemical Biosensor for Rapid Detection of SARS-CoV-2 Virus in 30 Seconds
|
By LabMedica International staff writers Posted on 16 Oct 2020 |

Image: Testing a nanotube-based electrochemical biosensor (Photo courtesy of University of Nevada)
A new COVID-19 rapid test that uses a nanotube-based electrochemical biosensor has shown successful lab results by detecting the SARS-CoV-2 virus in about 30 seconds.
Engineers and virologists at the University of Nevada (Reno, NV, USA) have teamed up to develop a novel COVID-19 testing approach based on a similar technology used in the past for detecting tuberculosis and colorectal cancer as well as detection of biomarkers for food safety. Using their expertise in detecting a specific biomarker in the breath of tuberculosis patients using a metal functionalized nano sensor, the researchers have developed a SARS-CoV-2 test that does not require a blood sample and is run using a nasal swab or even exhaled breath, which has biomarkers of COVID-19. The developed approach also has the potential for diagnosis of other respiratory viral diseases by identifying appropriate metallic elements to functionalize nanotubes.
The researchers first synthesized and prepared the antigenic protein of COVID-19 virus in their laboratory, SARS-CoV-2 receptor binding domain protein, for the preliminary testing and determining the sensitivity of the nano sensor. The team developed co-metal functionalized nanotubes as a sensing material for electrochemical detection of the protein. They confirmed the biosensor’s potential for clinical application by directly analyzing the RBD of the Spike glycoprotein on the sensor. The team now plans to move to the next step of sensor validation on the actual COVID-19 patients swabs stored in the Viral Transport Medium (VTM) and have applied for funding to develop a specific and inexpensive point-of-care sensor for a rapid detection of COVID-19 virus in saliva or breath of infected individuals.
“This is Point of Care testing to assess the exposure to COVID-19. We do not need a laboratory setting or trained health care workers to administer the test. Electrochemical biosensors are advantageous for sensing purposes as they are sensitive, accurate and simple,” said Professor Misra, in the University’s College of Engineering Chemical and Materials Department.
Related Links:
University of Nevada
Engineers and virologists at the University of Nevada (Reno, NV, USA) have teamed up to develop a novel COVID-19 testing approach based on a similar technology used in the past for detecting tuberculosis and colorectal cancer as well as detection of biomarkers for food safety. Using their expertise in detecting a specific biomarker in the breath of tuberculosis patients using a metal functionalized nano sensor, the researchers have developed a SARS-CoV-2 test that does not require a blood sample and is run using a nasal swab or even exhaled breath, which has biomarkers of COVID-19. The developed approach also has the potential for diagnosis of other respiratory viral diseases by identifying appropriate metallic elements to functionalize nanotubes.
The researchers first synthesized and prepared the antigenic protein of COVID-19 virus in their laboratory, SARS-CoV-2 receptor binding domain protein, for the preliminary testing and determining the sensitivity of the nano sensor. The team developed co-metal functionalized nanotubes as a sensing material for electrochemical detection of the protein. They confirmed the biosensor’s potential for clinical application by directly analyzing the RBD of the Spike glycoprotein on the sensor. The team now plans to move to the next step of sensor validation on the actual COVID-19 patients swabs stored in the Viral Transport Medium (VTM) and have applied for funding to develop a specific and inexpensive point-of-care sensor for a rapid detection of COVID-19 virus in saliva or breath of infected individuals.
“This is Point of Care testing to assess the exposure to COVID-19. We do not need a laboratory setting or trained health care workers to administer the test. Electrochemical biosensors are advantageous for sensing purposes as they are sensitive, accurate and simple,” said Professor Misra, in the University’s College of Engineering Chemical and Materials Department.
Related Links:
University of Nevada
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants
Channels
Clinical Chemistry
view channel
Chemical Imaging Probe Could Track and Treat Prostate Cancer
Prostate cancer remains a leading cause of illness and death among men, with many patients eventually developing resistance to standard hormone-blocking therapies. These drugs often lose effectiveness... Read more
Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
Creatinine has long been the standard for measuring kidney filtration, while cystatin C — a protein produced by all human cells — has been recommended as a complementary marker because it is influenced... Read moreMolecular Diagnostics
view channel
Four-Gene Blood Test Rules Out Bacterial Lung Infection
Lower respiratory tract infections (LRTIs) are among the most common reasons for antibiotic prescriptions, yet distinguishing bacterial infections from viral ones remains notoriously difficult.... Read more
New PCR Test Improves Diagnostic Accuracy of Bacterial Vaginosis and Candida Vaginitis
Bacterial vaginosis (BV) impacts approximately 25% of women of reproductive age, while up to 75% of women experience candida vaginitis (CV) at least once in their lifetime. Vaginal symptoms are one of... Read moreHematology
view channel
Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read moreImmunology
view channel
Gene Signature Test Predicts Response to Key Breast Cancer Treatment
DK4/6 inhibitors paired with hormone therapy have become a cornerstone treatment for advanced HR+/HER2– breast cancer, slowing tumor growth by blocking key proteins that drive cell division.... Read more
Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
Ductal carcinoma in situ (DCIS) accounts for about a quarter of all breast cancer cases and generally carries a good prognosis. This non-invasive form of the disease may or may not become life-threatening.... Read moreMicrobiology
view channelRapid POC Tuberculosis Test Provides Results Within 15 Minutes
Tuberculosis remains one of the world’s deadliest infectious diseases, and reducing new cases depends on identifying individuals with latent infection before it progresses. Current diagnostic tools often... Read more
Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples
Bloodstream infections in sepsis progress quickly and demand rapid, precise diagnosis. Current blood-culture methods often take one to five days to identify the pathogen, leaving clinicians to treat blindly... Read morePathology
view channelAI Tool Outperforms Doctors in Spotting Blood Cell Abnormalities
Diagnosing blood disorders depends on recognizing subtle abnormalities in cell size, shape, and structure, yet this process is slow, subjective, and requires years of expert training. Even specialists... Read more
AI Tool Rapidly Analyzes Complex Cancer Images for Personalized Treatment
Complex digital biopsy images that typically take an expert pathologist up to 20 minutes to assess can now be analyzed in about one minute using a new artificial intelligence (AI) tool. The technology... Read moreTechnology
view channel
AI Saliva Sensor Enables Early Detection of Head and Neck Cancer
Early detection of head and neck cancer remains difficult because the disease produces few or no symptoms in its earliest stages, and lesions often lie deep within the head or neck, where biopsy or endoscopy... Read more
AI-Powered Biosensor Technology to Enable Breath Test for Lung Cancer Detection
Detecting lung cancer early remains one of the biggest challenges in oncology, largely because current tools are invasive, expensive, or unable to identify the disease in its earliest phases.... Read moreIndustry
view channel
Abbott Acquires Cancer-Screening Company Exact Sciences
Abbott (Abbott Park, IL, USA) has entered into a definitive agreement to acquire Exact Sciences (Madison, WI, USA), enabling it to enter and lead in fast-growing cancer diagnostics segments.... Read more








 Analyzer.jpg)
